Enoxaparin versus unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction.
暂无分享,去创建一个
E. Antman | E. Braunwald | H. White | A. Budaj | D. Morrow | S. Murphy | C. McCabe | J. López-Sendón | K. Fox | M. Ruda | S. Guneri | Z. Sadowski | F. Jiang | C. Mccabe
[1] S. Yusuf,et al. Unfractionated and Low-Molecular-Weight Heparin as Adjuncts to Thrombolysis in Aspirin-Treated Patients With ST-Elevation Acute Myocardial Infarction: A Meta-Analysis of the Randomized Trials , 2005, Circulation.
[2] E. Antman,et al. Enoxaparin versus unfractionated heparin as antithrombin therapy in patients receiving fibrinolysis for ST-elevation myocardial infarction. Design and rationale for the Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction Treatment-Thrombolysis In Myocardial Infarction study 25 (E , 2005, American heart journal.
[3] Timi Study. Enoxaparin versus unfractionated heparin as antithrombin therapy in patients receiving fibrinolysis for ST- elevation myocardial infarction: Design and rationale for the Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction Treatment- Th , 2005 .
[4] G. Lamas,et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction--executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to revise the 1999 guidelines for the management of patients wi , 2004, Journal of the American College of Cardiology.
[5] P. Armstrong,et al. Efficacy and Safety of Tenecteplase in Combination With the Low-Molecular-Weight Heparin Enoxaparin or Unfractionated Heparin in the Prehospital Setting: The Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT)-3 PLUS Randomized Trial in Acute Myocardial Infarction , 2003, Circulation.
[6] E. Antman,et al. Early and long-term clinical outcomes associated with reinfarction following fibrinolytic administration in the Thrombolysis in Myocardial Infarction trials. , 2003, Journal of the American College of Cardiology.
[7] E. Antman. The Search for Replacements for Unfractionated Heparin , 2001, Circulation.
[8] E. Topol. A comparison of reteplase with alteplase for acute myocardial infarction. , 1998, The New England journal of medicine.
[9] J. Weitz. Low-molecular-weight heparins. , 1997, The New England journal of medicine.
[10] E. Antman. Hirudin in acute myocardial infarction. Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9B trial. , 1996, Circulation.
[11] M. Simoons. A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes. , 1996, The New England journal of medicine.
[12] E. Braunwald,et al. Prognostic significance of nonfatal reinfarction during 3-year follow-up: results of the Thrombolysis in Myocardial Infarction (TIMI) phase II clinical trial. The TIMI Investigators. , 1995, Journal of the American College of Cardiology.
[13] Frans Van de Werf,et al. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. , 1993, The New England journal of medicine.
[14] M. Pfisterer,et al. Effect of early intravenous heparin on coronary patency, infarct size, and bleeding complications after alteplase thrombolysis: results of a randomised double blind European Cooperative Study Group trial. , 1992, British heart journal.
[15] H. Hellstrom. Consequences of reocclusion after successful reperfusion therapy in acute myocardial infarction. , 1991, Circulation.
[16] A. Tonkin,et al. A Randomized Comparison of Intravenous Heparin With Oral Aspirin and Dipyridamole 24 Hours After Recombinant Tissue‐Type Plasminogen Activator for Acute Myocardial Infarction , 1991, Circulation.
[17] W. Daniel,et al. Increased Thrombin Levels During Thrombolytic Therapy in Acute Myocardial Infarction: Relevance for the Success of Therapy , 1991, Circulation.
[18] J. Hsia,et al. A comparison between heparin and low-dose aspirin as adjunctive therapy with tissue plasminogen activator for acute myocardial infarction. Heparin-Aspirin Reperfusion Trial (HART) Investigators. , 1990, The New England journal of medicine.
[19] R. Califf,et al. Consequences of reocclusion after successful reperfusion therapy in acute myocardial infarction. TAMI Study Group. , 1990, Circulation.
[20] Gruppo Italiano per lo Studio della Soprawivenza nell'Inf Miocardico.. MEDICAL SCIENCE GISSI-2: A factorial randomised trial of alteplase versus streptokinase and heparin versus no heparin among 12 490 patients with acute myocardial infarction , 1990, The Lancet.
[21] K. Lee,et al. A randomized controlled trial of intravenous tissue plasminogen activator and early intravenous heparin in acute myocardial infarction. , 1989, Circulation.
[22] J. Spann,et al. Factors influencing reocclusion after coronary thrombolysis for acute myocardial infarction. , 1986, The American journal of cardiology.
[23] S. M. Collins,et al. Rethrombosis after reperfusion with streptokinase: importance of geometry of residual lesions. , 1984, Circulation.